Spero Therapeutics (SPRO) Return on Equity (2017 - 2026)

Spero Therapeutics has reported Return on Equity for 10 years, with the latest figure at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity rose 2.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (up 2.0% YoY), and the FY2025 full-year result was 0.0%, up 1.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.0%, up from 0.0% in the prior quarter.
• The five-year high for Return on Equity was 0.0% in Q4 2023, with the low at 0.03% in Q3 2022.
• Historically, Return on Equity has averaged 0.01% across 5 years, with a median of 0.0% in 2023.
• Annual changes were most pronounced in 2022 — Return on Equity fell 2 bps — and 2023, when it increased 3 bps.
• Spero Therapeutics' Return on Equity stood at 0.01% in 2022, then surged by 145 bps to 0.0% in 2023, then tumbled by 489 bps to 0.01% in 2024, then surged by 115 bps to 0.0% in 2025, then surged by 36 bps to 0.0% in 2026.
• The last three Return on Equity figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.